JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Axelrod, J.
Right arrow Articles by Brodie, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Axelrod, J.
Right arrow Articles by Brodie, B. B.
Journal of Pharmacology And Experimental Therapeutics, Vol. 112, Issue 1, 49-54, 1954
Copyright © 1954 by American Society for Pharmacology and Experimental Therapeutics

MECHANISM OF THE POTENTIATING ACTION OF beta-DIETHYLAMINOETHYL DIPHENYLPROPYLACETATE

Julius Axelrod 1, Jules Reichenthal 1, and Bernard B. Brodie 1

1 Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Public Health Service, U. S. Department of Health, Education and Welfare, Bethesda, Maryland

beta-Diethylaminoethyl diphenylpropylacetate HCl (SKF 525-A) prolongs the duration of action and inhibits the rate of biotransformation of hexobarbital and pentobarbital in the body. The inhibitor also retards the demethylation of meperidine, aminopyrine and ephedrine.

It is concluded that SKF 525-A prolongs the duration of action of a variety of drugs primarily by inhibiting their rate of metabolic transformation.

Submitted on April 19, 1954




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. R. Franklin and L. B. Hathaway
2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) Revisited: Comparative Cytochrome P450 Inhibition in Human Liver Microsomes by SKF525A, Its Metabolites, and SKF-Acid and SKF-Alcohol
Drug Metab. Dispos., December 1, 2008; 36(12): 2539 - 2546.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 1, 1909-1958
Drug Metab. Dispos., January 1, 2008; 36(1): 1 - 5.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
A. H. Conney and J. J. Burns
Metabolic Interactions Among Environmental Chemicals and Drugs: Environmental chemicals that alter microsomal activity may influence the safety and efficacy of drugs
Science, November 10, 1972; 178(4061): 576 - 586.
[Abstract] [PDF]

Home page
 ScienceHome page
B. B. Brodie, J. Axelrod, J. R. Cooper, L. Gaudette, B. N. La Du, C. Mitoma, and S. Udenfriend
Detoxication of Drugs and Other Foreign Compounds by Liver Microsomes
Science, April 22, 1955; 121(3147): 603 - 604.
[PDF]

Home page
 ScienceHome page
A. Goldin, D. Dennis, J. M. Venditti, and S. R. Humphreys
Potentiation of Pentobarbital Anesthesia by Isonicotinic Acid Hydrazide and Related Compounds
Science, March 11, 1955; 121(3141): 364 - 365.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1954 by the American Society for Pharmacology and Experimental Therapeutics.